Amendments to the Claims

1. (previously presented) A compound or a pharmaceutically acceptable salt thereof represented by a formula below:



wherein

R and R' are independently C_1-C_5 alkyl, or together R and R' form a carbocyclic ring having from 3 to 8 carbon atoms;

RP_3 is hydrogen, or C_1-C_5 alkyl;

(L_{P1}) is $-(CH_2)_m$-O- ;

(L_{P2}) is



is

where m is 0, 1, or 2;

Z_P is a branched C_3-C_5 alkyl or 1-ethyl-1-hydroxypropyl;

Z_{TB} is selected from

-O-SO_2-(C_1-C_5 alkyl,)

-CO_2H,

-CO_2Me,

-CO_2Et,

-C(O)NH_2,

-C(O)NMe_2,

-C(O)NH-CH_2-C(O)OH,

-C(O)NH-CH_2-C(O)OMe,

-C(O)NH-CH_2-C(O)OEt,
-C(O)NH-CH_2-C(O)OiPr,
-C(O)NH-CH_2-C(O)OtBu,
-C(O)NH-CH(Me)-C(O)OH,
-C(O)NH-CH(Me)-C(O)OMe,
-C(O)NH-CH(Me)-C(O)OEt,
-C(O)NH-CH(Me)-C(O)iPr,
-C(O)NH-CH(Me)-C(O)tBu,
-C(O)NH-CH(Et)-C(O)OH,
-C(O)NH-$C(Me)_2$-C(O)OH,
-C(O)NH-$C(Me)_2$-C(O)OMe,
-C(O)NH-$C(Me)_2$-C(O)OEt,
-C(O)NH-$C(Me)_2$-C(O)iPr,
-C(O)NH-$C(Me)_2$-C(O)tBu,

provided that -(L_{TB})-Z_{TB} is substituted at either the 5 or 6 position of the benzothiophene ring.

2-6. (canceled)

7. (previously presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof,

wherein

R and R' are independently methy or ethyl;

RP_3 is hydrogen, methyl, or ethyl; and

(L_{P2}) is a bond or -CH(OH)-.

8-9. (canceled)

10. (previously presented) A compound according to claim 1 represented by formulae below or a pharmaceutically acceptable salt thereof:

C7)



C8)



C9)



C10)



C11)



C12)



C17)



C18)



C19)



C20)



C21)



C22)



11. (previously presented) The compound according to claim 1 represented by the structural formula AA or a pharmaceutically acceptable salt thereof:



(AA)

12. (previously presented) A compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein said compound is selected from



;



;



;



;



; or



.

13. (canceled)

14. (previously presented) A compound according to claim 1 wherein the pharmaceutically acceptable salt is a sodium or potassium salt.

15. (previously presented) A pharmaceutical formulation comprising the compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent.

16-19. (canceled)

20. (currently amended) A method of treating a mammal to ~~prevent or~~ alleviate the pathological effects of Osteoporosis, or Psoriasis, wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21. (original) The method of claim 20 for the treatment of psoriasis.

22. (original) The method of claim 20 for the treatment of osteoporosis.

23-35. (canceled)

36. (previously presented) A compound of according to Claim 1, or a pharmaceutically acceptable salt thereof,

R and R' are each ethyl;

RP_3 is methyl; and

(L_{P2}) is a –C(O)- or -CH(OH)-.

37. (previously presented) A compound according to claim 1 wherein Z_{TB} includes a carboxylic acid group functionalized as a N,N-diethylglycolamido ester or morpholinylethyl ester.

38. (new) A compound according to claim 11 wherein the pharmaceutically acceptable salt is a sodium or potassium salt.

39. (new) A pharmaceutical formulation comprising the compound according to claim 11 together with a pharmaceutically acceptable carrier or diluent.

40. (new) A method of treating a mammal to lleviate the pathological effects of Osteoporosis or Psoriasis, wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 11 or a pharmaceutically acceptable salt thereof.

41. (new) The method of claim 40 for the treatment of psoriasis.

42. (new) The method of claim 40 for the treatment of osteoporosis.